sorafenib has been researched along with eupalinolide a in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (eupalinolide a) | Trials (eupalinolide a) | Recent Studies (post-2010) (eupalinolide a) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 6 | 0 | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Z; Chen, D; Deng, X; Ding, W; Dong, F; Han, M; He, X; Jin, L; Li, J; Liu, D; Liu, H; Luo, W; Mu, J; Mu, X; Pan, L; Pang, Y; Wang, T; Wei, Y; Wu, Z; Zhang, H; Zhang, Y | 1 |
1 other study(ies) available for sorafenib and eupalinolide a
| Article | Year |
|---|---|
Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway.
Topics: Carcinoma, Hepatocellular; Ferroptosis; Humans; Lactones; Liver Neoplasms; MAP Kinase Signaling System; Reactive Oxygen Species; Sesquiterpenes, Germacrane; Sorafenib | 2022 |